ESG
Kwelio exists because medication non-adherence is one of the most preventable causes of suffering and avoidable healthcare cost in the world. Our core mission is inseparable from our ESG commitment — we measure our success not just by commercial performance, but by lives improved.
We are building in a region — the UAE and GCC — where chronic disease prevalence is among the highest globally. Diabetes, cardiovascular disease, and hypertension affect millions. Our platform is designed to serve this population equitably, regardless of nationality, language, or income level.
A software platform by design. Our adherence packaging uses minimal, recyclable materials. We are committed to carbon-neutral operations as we scale.
Reducing avoidable hospitalisations directly improves quality of life — particularly for lower-income patients who face the greatest cost burden of non-adherence. We price our B2B model so the end product is free for members.
Dual-entity structure separates data control (Lumio Holdings, ADGM) from data processing (Kwelio Labs, Dubai Media City). Designed for PDPL, GDPR, and UK GDPR compliance from day one.
Social impact
Data & privacy
Kwelio's architecture was designed with privacy as a foundation, not a feature. Member data is never sold. Insurers receive anonymised, aggregated adherence scores — not raw personal health information.
We are designed for compliance with UAE PDPL, ADGM Data Protection Regulations, GDPR, and UK GDPR. Our dual-entity structure — with Lumio Holdings as data controller and Kwelio Labs as data processor — reflects best-practice data governance.
All members retain the right to access, export, and delete their data at any time through the Pop by Kwelio app. No data is retained beyond the stated purposes outlined in our Privacy Policy.